Luan Linden Phillips is a senior analyst in the Research and Reviews team at the National Institute for Health Research Horizon Scanning Centre (NIHR HSC). The NIHR HSC provides horizon scanning intelligence about selected key new and emerging health technologies to NICE, the Department of Health and national NHS policy makers. Luan's responsibilities include pharmaceuticals and medical devices, and she has a particular interest in diagnostics.
Luan is an experienced health technology analyst with a broad knowledge of the health policy environment and market access issues that confront innovative new health technologies. As part of the NIHR HSC Reviews team, Luan produces and supervises a diverse range of tailored disease- and technology-specific reports to assist in NHS policy and commissioning decisions, engaging with key stakeholders in the health care landscape.
In addition to her horizon scanning position, Luan is also studying for a PhD (part-time) from the College of Medical and Dental Sciences at the University of Birmingham on the factors that influence the uptake and use of pharmaceuticals (see research section for further details).
MSc in Toxicology, University of Birmingham, 2000
BSc (Hons) in Biosciences (Microbiology), University of Birmingham, 1999
Luan qualified with a first class degree in microbiology in 1999, followed by a Masters degree in toxicology from the University of Birmingham in 2000. She continued to specialise in this field, spending two years as a poisons specialist at the National Poisons Information Service, before joining the NIHR HSC in 2002. She has maintained her interest in this field by continuing to teach this subject, as well as broader public health topics to medical students at undergraduate level, and is involved in training other health professionals in the methods of horizon scanning.
During her time at the NIHR HSC, Luan has produced many reports covering a diverse selection of health technologies, disease areas, patient groups and settings and has participated in conferences and panel sessions discussing the challenges affecting the use of new health technologies, which she has been able to explore further through her PhD
Diffusion and uptake of new health technologies; influence of the pharmaceutical industry in drug diffusion; early awareness and alert activities; health services research.
Luan’s field of research includes the adoption and diffusion of new innovative health technologies. In addition to having published and presented on the subject, she is also nearing the end of a PhD researching into the area of pharmaceutical diffusion.
PhD title: Pharmaceutical Industry Perspectives on Factors that Influence the Adoption and Diffusion of drugs in the UK: Four Case Studies.
Outline: A predominantly qualitative project utilising in-depth interviews with senior pharmaceutical marketing personnel across multiple case studies to explore industry opinions on adoption influences for drugs in the UK.
Tayo A, Ellis J, Linden Phillips L, Simpson S, Ward DJ. Emerging point of care tests for influenza: innovation or status quo. Influenza Other Respi Viruses. 2012; 6 (4) 291-298
Plüddermann A, Heneghan C, Thompson M, Roberts N, Summerton N, Price C, Linden Phillips L, Packer C. Prioritisation criteria for the selection of new diagnostic technologies for evaluation. BMC Health Services Research 2010; 10:109.
Linden L, Vondeling H, Packer C, Cook A. Does NICE only appraise new pharmaceuticals? International Journal of Technology Assessment in Health Care 2007; 23(3): 349-353.
Gao L, Linden L, Parsons NJ, Cole JA, Smith H. Uptake of metabolites by gonococci grown with a lactate in a medium containing glucose: evidence for a surface location of the sialyltransferase. Microb Pathog 2000; 28 (5); 257-266